Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
IPO Year: 2014
Exchange: NASDAQ
Website: eledon.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/13/2022 | $25.00 → $15.00 | Overweight | Cantor Fitzgerald |
| 11/24/2021 | $35.00 → $25.00 | Buy | HC Wainwright & Co. |
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its common stock at a price of $3.65 per share and (ii) pre-funded warrants to purchase up to an aggregate of 4,931,507 shares of common stock at a price of $3.649 per pre-funded warrant. The pre-funded warrants will be immediately exercisable and will have an exercise price of $0.001 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $85 million. All of the shares of common stock and pre-funded
IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 8:35 a.m. ET. To register in advance for the fireside chat webcast, sign up here. A webcast replay will be accessible following the live session on the Company's website under Events. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life
IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that it has successfully completed enrollment for its Phase 2 BESTOW clinical trial, which is designed to assess the safety and efficacy of its investigational immunosuppression therapy tegoprubart for the prevention of organ rejection in patients undergoing kidney transplantation. The trial reached its target enrollment of 120 participants approximately four months earlier than originally planned. "We are very pleased to achieve this critical milestone ahead of schedule in our BESTOW trial," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. "Th
Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment) enrolled in Phase 2 BESTOW trial Completed an oversubscribed $50 million private placement; Company expects sufficient liquidity through December 2025 IRVINE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported recent business highlights for its second quarter 2024. "We have entered the second half of the year with a strong balance sheet following our oversubscribed $50 million private placement and we are highly encourage
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial assessing tegoprubart for the prevention of rejection in kidney transplantation. "As of this week, we have already enrolled two-thirds of the projected study participants across sites in the United States, Europe and Latin America," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. "We are grateful to the participants and their clinical teams, whose high level of interest enabled us to achieve this level of enrollment in our Phase 2 BESTOW trial. This progress underscores t
IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company's management team will be hosting one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism, on July 9, 2024, in Boston, MA. About Eledon Pharmaceuticals and tegoprubart Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company's lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD4
Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 post-transplant of 70.5 mL/min/1.73m² Mean eGFR measured above 60 mL/min/1.73m² at all reported time points after day 30 post-transplant IRVINE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today presented updated data from the Company's ongoing open-label Phase 1b trial and open-label extension study evaluating tegoprubart for the prevention of organ rejection in kidney transplant patients. Results from the poster, titled "Biomarkers of Infl
Completed oversubscribed $50 million private placement First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation Tegoprubart used as part of immunosuppressive treatment following the first-ever kidney xenotransplant IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its first quarter 2024 operating and financial results and reviewed recent business highl
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the Company will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will present a poster that features updated data from Eledon's ongoing open-label Phase 1b trial and open-label extension study evaluating tegoprubart for the prevention of rejection in patients undergoing kidney transplantation. Details on the poster presentation are below: Title: Biomarkers of Inflammation and eGFR in an Ongoing Phase 1B Study of an Anti-CD40L Antibody Tegoprubart, for the Prevention of Rejection in Kidney Transp
First participant dosed in clinical trial at University of Chicago Medicine assessing the use of tegoprubart to prevent islet cell transplant rejection in patients with type 1 diabetes Company reports updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation IRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with a novel immunosuppression regimen including tegoprubart, the company's novel anti-CD40L antibody, which is in development for th
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
SC 13G/A - Eledon Pharmaceuticals, Inc. (0001404281) (Subject)
HC Wainwright & Co. analyst Vernon Bernardino reiterates Eledon Pharma (NASDAQ:ELDN) with a Buy and maintains $16 price target.
Gainers Akso Health Group (NASDAQ:AHG) shares rose 11.4% to $0.79 during Friday's after-market session. The company's market cap stands at $116.0 million. China SXT Pharmaceuticals (NASDAQ:SXTC) shares increased by 10.43% to $1.27. The company's market cap stands at $1.1 million. CareCloud (NASDAQ:CCLD) stock increased by 10.07% to $2.84. The company's market cap stands at $45.7 million. The company's, Q1 earnings came out 3 days ago. Eledon Pharma (NASDAQ:ELDN) shares moved upwards by 9.63% to $3.31. The company's market cap stands at $125.5 million. OneMedNet (NASDAQ:ONMD) shares increased by 7.52% to $0.5. The market value of their outstanding shares is at $11.9 million. Reshape Lif
HC Wainwright & Co. analyst Vernon Bernardino reiterates Eledon Pharma (NASDAQ:ELDN) with a Buy and maintains $16 price target.
Eledon Pharma (NASDAQ:ELDN) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 54.67 percent increase over losses of $(0.75) per share from the same period last year.
Tuesday, Eledon Pharmaceuticals Inc (NASDAQ:ELDN) announced that the first participant in an investigator-led clinical trial has received an islet cell transplant and is being treated with tegoprubart for the prevention of pancreatic islet cell transplant rejection in type 1 diabetes patients. The company also reported updated data from its ongoing Phase 1b trial as of April 2024 from 13 participants, demonstrating that tegoprubart is generally safe and well-tolerated and supports tegoprubart’s potential to protect organ function in patients undergoing kidney transplantation. Aggregate mean estimated glomerular filtration rate (eGFR) – a measure of kidney function – measured above 60 m
HC Wainwright & Co. analyst Vernon Bernardino maintains Eledon Pharma (NASDAQ:ELDN) with a Buy and raises the price target from $13 to $16.
Gainers FibroGen (NASDAQ:FGEN) shares rose 37.1% to $1.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $158.1 million. The company's, Q1 earnings came out yesterday. Envoy Medical (NASDAQ:COCH) stock moved upwards by 23.54% to $4.25. The company's market cap stands at $83.2 million. iSpecimen (NASDAQ:ISPC) shares rose 21.18% to $0.33. The company's market cap stands at $3.0 million. The company's, Q1 earnings came out today. NovaBay Pharmaceuticals (AMEX:NBY) shares moved upwards by 20.87% to $0.11. The company's market cap stands at $3.9 million. GT Biopharma (NASDAQ:GTBP) shares rose 19.25% to $3.84. The market value of their outstanding shar
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
4 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
3 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
3 - Eledon Pharmaceuticals, Inc. (0001404281) (Issuer)
424B5 - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
424B5 - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
EFFECT - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
8-K - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
S-3 - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
10-Q - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
10-Q/A - Eledon Pharmaceuticals, Inc. (0001404281) (Filer)
Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection Tegoprubart used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human Additional data from 11 participants in Phase 1b trial in kidney transplantation demonstrated that tegoprubart was generally safe and well tolerated, successfully prevented rejection and permitted above historical average post-transplant kidney function IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full year 2023 opera
Reported updated data from ongoing Phase 1b trial in kidney transplantation demonstrating tegoprubart treatment successfully prevented kidney transplant rejection and was generally safe and well-tolerated Dosed first participants in Phase 2 BESTOW trial in kidney transplantation Tegoprubart dosed in second-ever pig to human xenotransplant procedure IRVINE, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced a summary of 2023 accomplishments and provided guidance for anticipated upcoming 2024 milestones. 2023 Key Highlights Reported updated data from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection i
Reported updated data from ongoing Phase 1b trial further supporting the potential of tegoprubart as a novel kidney transplant immunosuppressive therapy to prevent rejection and better preserve organ function First participant dosed in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of rejection in kidney transplantation IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its third quarter operating and financial results and reviewed recent business highlights. "We were thrilled recently to report updated results from our ongoing Phase 1b study that continue to validate tegoprubart's potential as an immuno
IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company's clinical development programs. "We are pleased to welcome Dr. Katz to the Eledon team," said David-Alexandre C. Gros, M.D., Eledon Chief Executive Officer. "Dr. Katz brings a wealth of knowledge in the surgical transplantation field together with extensive experience designing and overseeing clinical trials for immunosuppressive treatments. We look forward to his leadership and contributions as we continue to advance tegoprubart for the prevention of rejecti
IRVINE, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced the appointment of Allan Douglas Kirk, M.D., Ph.D., to its Board of Directors. Dr. Kirk is internationally recognized for his work in organ transplantation, with a specialized focus on kidney transplants and transplant immunology. He is currently Chairman of the Department of Surgery and Surgeon-in-Chief at Duke University School of Medicine. He is also the David C. Sabiston, Jr. Professor of Surgery, a Professor of Integrative Immunobiology, and a Professor of Pediatrics at Duke. "We are pleased to have Dr. Kirk join our Board of Directors at a pivotal time at the compa
IRVINE, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced the appointment of James Robinson to its Board of Directors effective October 1, 2023. Mr. Robinson is a seasoned biopharmaceutical executive with over 30 years of experience in the industry, most recently serving as Chief Executive Officer and Director of Urovant Sciences until its merger with Sumitomo Pharma America on July 1, 2023. "I am pleased to welcome Jim to our Board and look forward to working with him," said David-Alexandre C. Gros, M.D., Chief Executive Officer. "Jim joins our Board at a pivotal time in our mission to bring a novel and much-needed new treatm
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced the appointment of Jan Hillson, M.D., to the company's Board of Directors. Dr. Hillson currently serves as Senior Vice President of Clinical Development at Alpine Immune Sciences, a clinical stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer an
Cantor Fitzgerald resumed coverage of Eledon Pharmaceuticals with a rating of Overweight and set a new price target of $15.00 from $25.00 previously
HC Wainwright & Co. reiterated coverage of Eledon Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $35.00 previously
SVB Leerink reiterated coverage of Eledon Pharmaceuticals with a rating of Outperform and set a new price target of $33.00 from $34.00 previously
Cantor Fitzgerald initiated coverage of Eledon Pharmaceuticals with a rating of Overweight and set a new price target of $25.00
SVB Leerink initiated coverage of Eledon Pharmaceuticals with a rating of Outperform
SVB Leerink initiated coverage of Eledon Pharmaceuticals with a rating of Outperform and set a new price target of $34.00
Data from 11 participants demonstrates tegoprubart successfully prevented kidney transplant rejection and was generally safe and well-tolerated Aggregate mean eGFR was above 70 mL/min/1.73m2 at all reported time points after day 90 supporting tegoprubart's potential to protect organ function in patients undergoing kidney transplantation Eledon will host a conference call today at 5:00 p.m. ET IRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported results from the Company's ongoing Phase 1b open-label trial evaluating tegoprubart for the prevention of rejection in patients undergoing de novo kidney transplantation. Results
Reported open-label data from ongoing Phase 1b trial of tegoprubart in kidney transplantation demonstrating mean eGFRs from 3 participants above 70 mL/min/1.73m2 at measured timepoints Completed financing of up to $185 million, with $35 million upfront, to fund the Company through the Phase 2 BESTOW kidney transplant trial, subject to achieving specific milestones Conference call today at 4:30 p.m. ET IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its first quarter operating and financial results and reviewed recent business highlights. "Eledon made significant progress this year in advancing the clinical developmen
IRVINE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that it plans to release financial results for the first quarter ended March 31, 2023 on Thursday, May 11, after the close of trading. Eledon's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Details: Thursday, May 11, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific TimeToll Free: 888-886-7786International: 416-764-8658Conference ID: 11107025Webcast: https://ir.eledon.com/events-and-presentations/events After the live webcast, the event will be archived on Eledon's website for one year. About Eledon Phar
`Four patients enrolled in open-label Phase 1b kidney transplant trial with clinical data on first three patients to be presented at the World Congress of Nephrology (WCN) on March 31, 2023 Safety data on sixteen patients enrolled in open-label Phase 2 IgA nephropathy trial also to be presented at the World Congress of Nephrology Company to continue to prioritize and focus resources on the advancement of tegoprubart in kidney transplantation Conference call today at 4:30 PM ET IRVINE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its fourth quarter and full-year 2022 operating and financial results and reviewed recent bu
IRVINE, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Thursday, March 30, after the close of trading. Eledon's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Details:Thursday, March 30, 2023 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific TimeToll Free: 877-300-8521International: 412-317-6026Conference ID: 10175955Webcast: https://ir.eledon.com/events-and-presentations/events After the live webcast, the event will be archived on Eledon's website for one ye
Received FDA clearance of IND application to evaluate tegoprubart in a Phase 2 trial for the prevention of rejection in patients receiving a kidney transplant Dosed initial two patients in ex-U.S. Phase 1b trial evaluating tegoprubart for the prevention of rejection in patients receiving a kidney transplant Received FDA clearance of IND application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN) Conference call today at 4:30 PM ET IRVINE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN) today reported its third quarter 2022 operating and financial results and reviewed recent business highlights. "The third quarter wa
IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), today announced that it plans to release financial results for the third quarter ended September 30, 2022 on Monday, November 14, after the close of trading. Eledon's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Details:Monday, November 14, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific TimeToll Free: 877-300-8521International: 412-317-6026Conference ID: 10171988Webcast: https://ir.eledon.com/events-and-presentations/events After the live webcast, the event will be archived on Eledon's website for one year. About E
Received FDA clearance of IND application for Phase 2 trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients First patient dosed in Phase 1b trial evaluating tegoprubart for the prevention of rejection in kidney transplant recipients in Canada, the United Kingdom and Australia Reported positive topline results from Phase 2a trial of tegoprubart demonstrating safety, target engagement, and biomarker response in patients living with amyotrophic lateral sclerosis (ALS) Tegoprubart received Orphan Drug Designation from the U.S. FDA for the prevention of allograft rejection in pancreatic islet cell transplantation Conference call today at 4:30 PM ET IRV
Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ:ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that it plans to release financial results for the second quarter ended June 30, 2022 on Thursday, August 11, after the close of trading. Eledon's management team will host a conference call and webcast beginning at 4:30 p.m. ET. Conference Call and Webcast Details:Thursday, August 11, 2022 at 4:
Tegoprubart was well-tolerated, with no drug-related serious adverse eventsDose dependent target engagement was demonstrated, and ALS associated pro-inflammatory biomarkers were both observed and significantly reduced in a dose dependent mannerTarget engagement and level of pro-inflammatory biomarker reduction were associated with a trend in the slowing of disease progression as measured by ALSFRS slope when compared to a cohort from the ALS PRO-ACT databaseBiomarkers significantly reduced included biomarkers also associated with IgA nephropathy and kidney allograft transplant rejectionEledon management will host a webcast and conference call regarding these clinical results at 8:00 a.m. ET